Zacks Investment Research upgraded shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) from a hold rating to a buy rating in a research report report published on Tuesday morning. Zacks Investment Research currently has $11.00 price objective on the stock.

According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “

Other equities research analysts also recently issued research reports about the company. Canaccord Genuity set a $20.00 price objective on Karyopharm Therapeutics and gave the company a buy rating in a research report on Saturday, August 6th. HC Wainwright reissued a buy rating on shares of Karyopharm Therapeutics in a research report on Tuesday, November 8th. Wedbush reissued an outperform rating and set a $14.00 price target on shares of Karyopharm Therapeutics in a research report on Tuesday, November 8th. Jefferies Group reissued a buy rating and set a $12.00 price target on shares of Karyopharm Therapeutics in a research report on Tuesday, November 8th. Finally, Robert W. Baird reissued a positive rating and set a $16.00 price target on shares of Karyopharm Therapeutics in a research report on Tuesday, September 6th. One analyst has rated the stock with a sell rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $15.47.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Shares of Karyopharm Therapeutics (NASDAQ:KPTI) opened at 9.67 on Tuesday. Karyopharm Therapeutics has a 52-week low of $4.83 and a 52-week high of $19.41. The company’s market capitalization is $398.82 million. The stock’s 50 day moving average price is $8.75 and its 200 day moving average price is $8.32.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Monday, November 7th. The company reported ($0.69) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.81) by $0.12. On average, equities research analysts forecast that Karyopharm Therapeutics will post ($3.00) earnings per share for the current fiscal year.

In related news, insider Ran Frenkel sold 3,309 shares of the stock in a transaction that occurred on Monday, November 14th. The stock was sold at an average price of $10.06, for a total value of $33,288.54. Following the completion of the transaction, the insider now directly owns 14,691 shares of the company’s stock, valued at approximately $147,791.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 14.79% of the stock is owned by corporate insiders.

A number of institutional investors have recently modified their holdings of KPTI. Wellington Management Group LLP raised its position in shares of Karyopharm Therapeutics by 631.9% in the first quarter. Wellington Management Group LLP now owns 1,269,485 shares of the company’s stock worth $11,323,000 after buying an additional 1,096,029 shares during the period. Baker BROS. Advisors LP acquired a new position in shares of Karyopharm Therapeutics during the third quarter worth about $2,111,000. New Leaf Venture Partners L.L.C. raised its position in shares of Karyopharm Therapeutics by 1,723.5% in the second quarter. New Leaf Venture Partners L.L.C. now owns 222,947 shares of the company’s stock worth $1,496,000 after buying an additional 210,721 shares during the period. Vanguard Group Inc. raised its position in shares of Karyopharm Therapeutics by 18.5% in the second quarter. Vanguard Group Inc. now owns 816,444 shares of the company’s stock worth $5,478,000 after buying an additional 127,714 shares during the period. Finally, Candriam Luxembourg S.C.A. raised its position in shares of Karyopharm Therapeutics by 68.8% in the third quarter. Candriam Luxembourg S.C.A. now owns 270,000 shares of the company’s stock worth $2,627,000 after buying an additional 110,000 shares during the period. 49.20% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Karyopharm Therapeutics Inc. (KPTI) Upgraded to Buy by Zacks Investment Research” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2016/11/23/karyopharm-therapeutics-inc-kpti-upgraded-to-buy-by-zacks-investment-research.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

5 Day Chart for NASDAQ:KPTI

Receive News & Stock Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related stocks with our FREE daily email newsletter.